Raymond James, Cantor, BofA and Citizens Highlight Underappreciated Opportunities in Camp4, Benitec, Immunic and Others

Analysts see attractive risk/reward in Camp4’s SYNGAP1 program, Benitec’s gene therapy, Immunic’s MS trials, Pharvaris and Microbot’s robotic system.